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Background/aim: The aim of our study was to elucidate the role of polymorphisms in AR, CYP1B1, CYP19, and SRD5A2 genes for
prostate cancer (PC) development in Bulgarian patients.
Materials and methods: We genotyped 246 PC patients and 261 controls (155 with benign prostate hyperplasia and 107 healthy
population controls) using direct sequencing, PCR-RFLP, SSCP, and fragment analysis.
Results: The allele and genotype frequencies of most of the studied variants did not differ significantly between cases and controls.
Increased frequencies of the C/C genotype and C allele of rs1056837 in CYP1B1, and genotype 7/8 of the (TTTA)n repeat polymorphism
in CYP19, were observed in patients in comparison with controls.
The 8/9 and the 7/12 genotypes of (TTTA)n in CYP19 showed suggestive evidence for association with decreased prostate cancer risk
and the risk for aggressive disease, respectively. The haplotype analysis revealed 2 CYP1B1 haplotypes associated with PC risk reduction.
Conclusion: Some CYP1B1 haplotypes and genotypes of the CYP19 (TTTA)n repeat appeared to be associated with disease risk or
aggressiveness in Bulgarian PC patients. In contrast, the SRD5A2 polymorphisms (V89L and (TA)n repeat), the CAG repeat in AR, and
the Arg264Cys variant in CYP19A1 are most likely not implicated in prostate carcinogenesis.
Key words: Association study, polymorphisms, prostate cancer, AR, CYP1B1, CYP19, SRD5A2

1. Introduction
1.1. Epidemiology
Benign and malignant disorders of the prostate are among
the most common diseases affecting males, particularly
in industrialized countries (1). Prostate cancer (PC) has
been recognized as a clinical entity since antiquity, when
it was first described by ancient Egyptians, while surgical
procedures to remove the prostate were developed more
than 100 years ago. However, the availability of highly
accessible blood tests for prostate-specific antigen (PSA)
has revolutionized the diagnosis of PC over the past 3
decades (2). Recent statistics demonstrate that PC is now
the second leading cause of cancer death and the most
commonly diagnosed malignancy in men in developed
countries as a result of the increased availability of
prostate-specific antigen testing (1,3–6).
* Correspondence: darina_kachakova@mmcbg.org
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PC was the second most common malignancy of all
male cancers in Bulgaria in 2010 (11.2%) with 1734 new
cases and it was the third leading cause for cancer deaths
among males (8.1%). The expected number of new PC
cases for 2013 with 95% confidence interval is 1851 (7).
1.2. Risk factors
Despite the substantial health impact of PC, the underlying
etiology is still relatively poorly understood, with both
genetic predisposition and environmental factors likely to
be contributing to the risk of the disease (5). It is believed
that the development of PC is a multiphase process and
that the disease is heterogeneous (5). The only established
risk factors are age, race, and family history (8). Evidence
exists that the steroid hormone pathway and the genes
involved in the metabolism of estrogens and androgens
or having receptor function affect the risk of PC (9).
Androgens are essential for the development, growth,
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and secretory activities of the prostate, whereas estrogens
modulate these effects (9). A mutagenic effect of estrogen
metabolites has long been hypothesized. Animal studies
support this hypothesis, evidenced by an increased risk of
prostatic dysplasia and carcinoma with estrogen treatment
in a Noble rat model (10).
Some authors believe that high estrogen and low
testosterone lead to the development of inflammation
upon aging and the emergence of premalignant lesions (1),
but others have shown that administration of testosterone
induces prostate tumors in laboratory animals and PC
regress after antiandrogen therapy (11).
The inconsistency of data from a variety of
epidemiological studies might be due to the different
measurements of plasma steroids, ethnic variability,
and heterogeneity of the genetic background among
individuals. In particular, single nucleotide polymorphisms
(SNPs) of genes involved in both the metabolism and
action of steroid hormones may be primarily implicated in
the susceptibility to PC (12). Association between PC risk
and SNPs in genes involved in sex hormone-related steroid
pathways has been observed in different studies, providing
further insight into the genetic basis of this disease (13,14).
The goal of the present study was to investigate the
association of PC and polymorphisms in genes implicated
in androgen metabolism such as AR, CYP1B1, CYP19,
and SRD5A2 in a cohort of Bulgarian patients and
controls. All selected polymorphisms were previously
examined in other populations and conflicting results
have been reported due to different ethnic groups, study
designs, sample sizes, environmental differences, genetic
admixtures, and ascertainment bias.
2. Materials and methods
2.1. Study population (participants)
Blood samples of patients with benign prostatic
hyperplasia (BPH) and PC were collected during their
annual screening in the Clinic of Urology/Department
of Urology, Alexandrovska University Hospital, Medical
University of Sofia. For-cause biopsies were recommended
for participants with abnormal digital rectal examinations
and/or an increase in prostate-specific antigen. All subjects
were of Bulgarian ethnicity. Each participant provided
written informed consent according to protocols approved
by ethical review board of the University.
We genotyped 246 patients with PC and 261 controls.
The clinical characteristics of the PC cases are given in
Table 1. The Gleason scoring system was used to classify
tumors as low-grade (Gleason score of ≤7) or high-grade
(Gleason score of >7).
The controls were matched to PC patients for age within
5-year categories. They included 155 individuals with
BPH and normal PSA levels and 107 healthy individuals

Table 1. Clinical characteristics of the PC cases
Parameter

N

Mean age

69.25 (SD = 8.16)

Mean PSA, ng/ml

34.56 (SD = 55.36)

PSA level at diagnosis
< 10 ng/ml

86

10 - 30 ng/ml

91

> 30ng/ml

64

Unknown

5

Pathologic Gleason score
≤6

103

7

72

≥8

71

Pathologic T stage
T1

26

T2

123

T3

84

T4

13

Nodal invasion
N0

166

N1

80

Metastasis
M0

210

M1

36

Age at onset, yr
≤ 64

67

> 64

172

PSA = prostate specific antigen

with unknown BPH and PSA status selected from the
DNA biobank of the Molecular Medicine Center, Medical
University of Sofia. The mean PSA value among controls
with BPH was 1.71 ng/mL.
2.2. DNA isolation and genotyping
DNA was isolated from blood samples using the Chemagic
Magnetic Separation Station (CHENAGEN). The quality
of isolated DNA was checked by agarose gel electrophoresis
and the concentration was measured using a NanoDrop
spectrophotometer (Thermo Scientific).
For the association study, 9 polymorphisms in 4 genes
related to androgen metabolism were selected: CAG repeat
polymorphism in exon 1 of AR, rs1800440 (Asn453Ser,
4390A > G, CYP1B1*4), rs1056837 (Asp449Asp, 4379C
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> T), rs1056836 (Leu432Val, 4326C > G CYP1B1*3),
rs1056827 (Ala119Ser, 355G > T CYP1B1*2) in CYP1B1,
rs700519 (Arg264Cys, R264C, 27142C > T) and (TTTA)
n in CYP19, rs523349 (Val89Leu), and rs10529926 ((TA)
n repeat polymorphism in 3’UTR) in SRD5A2. They were
chosen according to the following criteria: 1) likely to be
functional, 2) to have previously been associated with PC,
and 3) to have minor allele frequency (MAF) of >0.1.
The genetic analysis was carried out with standard
methods. The repeat polymorphisms in CYP19, SRD5A2,
and AR were analyzed by fragment analysis on an ABI
Prism 3130xl Genetic Analyzer (Applied Biosystems) after
PCR amplification. The number of repeats was determined
using molecular weight DNA standard GeneScan 500 Rox
(Life Technologies). To confirm the results, some samples
were sequenced.
2.2.1. CYP1B1 SNPs
The SNPs in the CYP1B1 gene were genotyped by
polymerase chain reaction (PCR) amplification followed
by direct sequencing using an ABI Prism 3130xl Genetic
Analyzer (Applied Biosystems). The cycling conditions
for genotyping the SNPs in exons 2 and 3 were as follows:
exon 2 - 5 min at 95 °C and 35 cycles consisting of 40 s at
95 °C, 40 s at 55 °C, and 50 s at 72 °C, with a final extension
of 5 min at 72 °C; exon 3 - 5 min at 95 °C and 35 cycles
consisting of 30 s at 95 °C, 40 s at 56 °C, and 1 min at 72
°C, with a final extension of 7 min at 72 °C.
2.2.2. AR (CAG)n
PCR reactions for (CAG)n repeat polymorphism were
carried out under the following conditions: 95 °C for 7
min; 35 cycles of 95 °C for 40 s, 66 °C for 40 s, and 72 °C
for 1 min; and a final extension at 72 °C for 7 min. The
number of repeats was determined using an ABI Prism
310 genetic analyzer running in parallel with a molecular
weight DNA marker-Rox. To confirm the results, some
samples were sequenced.
2.2.3. SRD5A2 (TA)n
The (TA)n marker was genotyped using the following
cycling conditions: 95 °C for 5 min; 35 cycles of 94 °C for
30 s, 55 °C for 1 min, and 72 °C for 1 min; and a final
extension at 72 °C for 5 min.
2.2.4. CYP19 (TTTA)n
The (TTTA)n repeat polymorphism was amplified in PCR
reactions implemented as follows: after a first denaturation
step of 11 min at 95 °C, reactions were submitted to 35
cycles consisting of 30 s at 94 °C, 30 s at 51 °C, and 30 s at
72 °C. A final extension of 10 min at 72 °C was performed,
and then 3 µL of each PCR product was mixed with 9.25
µL of deionized formamide and 0.75 µL of a molecular
marker (GeneScan 500 Rox). The fragments were then
separated by capillary electrophoresis.

628

2.2.5. SRD5A2 V89L
To detect the V89L polymorphism, PCR combined with
restriction fragment length polymorphism (RFLP) was
used. Briefly, PCR was carried out in a final volume of 20
µL containing 50 ng of genomic DNA. After a first step
of 11 min at 95 °C, reactions were submitted to 35 cycles
consisting of 30 s at 94 °C, 30 s at 60 °C, and 30 s at 72 °C.
A final extension of 10 min at 72 °C was then performed.
After PCR amplification and testing of the products on
2% agarose gel electrophoresis, 10 µL of PCR product
was digested with 5 units of RsaI in a final volume of 20
µL. Digestion was performed overnight at 37 °C. The
products were then separated on 3% agarose gel stained
with ethidium bromide to identify the base pair change.
The genotyping was done blind to case or control status.
2.2.6. CYP19 Arg264Cys
The CYP19 Arg264Cys (rs700519) substitution, resulting
from C-to-T polymorphism at codon 7, was detected
using 2 different methods: the single-strand conformation
polymorphism (SSCP) method and the RFLP method. To
confirm the accuracy of the 2 methods used, we sequenced
some PCR products on an ABI Prism 310 genetic analyzer
(Applied Biosystems). The cycling conditions were as
follows: 95 °C for 5 min, 35 cycles of 94 °C for 30 s, 55 °C
for 30 s, and 72 °C for 1 min, with a final extension at 72 °C
for 5 min. PCR products were then tested by 2% agarose
gel electrophoresis containing ethidium bromide. For
SSCP analysis, PCR products (7 µL) were mixed with 10 µL
of denaturing solution, incubated at 95 °C for 5 min, and
chilled immediately on ice. Samples were electrophoresed
on 15% 37.5:1 acrylamide:bis-acrylamide gel at 18 °C and
2000 V/cm for 4 h in 1X TBE buffer. After electrophoresis,
gels were silver stained by Budowle method. For RFLP
analysis, 10 µL of PCR products were digested with 5
units of Sfa NI in a final volume of 20 µL. Digestion was
performed overnight at 37 °C. The products were then
separated on 3% agarose gel containing ethidium bromide.
Then fragments were visualized by UV illumination.
Fragment sizes were estimated by comparison to a
ladder on the same gel. The C-to-T substitution creates a
recognition site for the Sfa NI restriction enzyme.
The sequences of the all primers used are shown in
Table 2.
2.3. Statistics
A chi-square test was used to verify the Hardy–Weinberg
equilibrium in haplotype analysis with HaploView 4.0
(Broad Institute of MIT & Harvard). The Fisher exact test
was used to compare the distribution of genotypes and
alleles between PC cases and controls (BPH and population
controls), between PC cases and BPH controls, between PC
cases and population controls, and between BPH controls
and population controls. This test was performed using
the online tools Vassar Stats (http://vassarstats.net/) and
PLINK v.1.07 (http://pngu.mgh.harvard.edu/~purcell/
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Table 2. Primers sequences used for genotyping and their annealing temperatures
Gene and studied polymorphisms
AR, (CAG)n repeat polymorphism
SRD5A2, rs523349 (V89L)
SRD5A2, (TA)n repeat (rs10529926)
CYP19, rs700519 (Arg264Cys)
CYP19, (TTTA)n repeat polymorphism
CYP1B1, rs1800440 (S453N); rs1056837 (D449D) and
rs1056836 (V432L)
CYP1B1, rs1056827 (A119S)

Primer sequence
F 5’- TCCAGAATCTGTTCCAGAGCGTGC- 3’
R 5’- GCTGTGAAGGTTGCTGTTCCTCAT – 3’
F 5’ GCCACCTGGGACGTTACTTCTG-3’
R 5’- TCCTTGGCGTTCCTCGGTGC-3’
F 5’-*Fam-GAAAACTGTCAAGCTGCTG-3’
R 5’-GGCAGAACGCCAGGAGAC-3’
F 5’- CGCTAGATGTCTAAACTGAG-3’
R 5’-CATATGTGGCATGGGAATTA-3’
F 5’-*Hex-TTATGAAAGGTAAGCAGGTACTTAG-3’
R 5’-GTCGTGAGCCAAGGTCACT-3’
F 5’-GCCTATTTAAGAAAAAGTGGAATTAAA-3’
R 5’-ATTCATTTTCGCAGGCTCAT-3’
F 5’-CCCATAGTGGTGCTG AATGG-3’
R 5’-TGTCCAGGATGAAGTTGCTG-3’

plink/). One-tailed and 2-tailed P-values were calculated.
P < 0.05 was considered significant. A separate test for
deviation from Hardy–Weinberg equilibrium was made
with an online tool from Helmholtz Zentrum München
(https://www.helmholtz-muenchen.de/) using the Pearson
P-values. Unconditional logistic regression was also used
for comparisons between cases and controls and for risk
attribution. This analysis was performed with SPSS 20.
Statistical epistasis was evaluated with PLINK v1.07.
3. Results
In total 9 polymorphic variants were genotyped in 507
samples. All variants were successfully genotyped in >90%
of the samples. The distributions of the genotypes and
the alleles of CYP1B1, CYP19, and SRD5A2 SNPs in PC
patients and controls (BPH and population controls) are
shown in Table 3. The allele and genotype distribution of
repeat polymorphisms in SRD5A2 and CYP19 in patients
and controls are shown in Table 4 and Table 5, respectively.
All genotype frequencies in patients with PC and
controls follow the Hardy–Weinberg equilibrium for all
SNPs, except SRD5A2 V89L (P = 0.0047 for cases and P
= 0.03 for controls). The deviation from Hardy–Weinberg
equilibrium might be due to the action of selective
pressure on the population or might be influenced by the
genotyping method. The frequencies among controls in
other studies summarized by Li et al. also deviated from
Hardy–Weinberg equilibrium (15).

Annealing
temperature
66ºC
60ºC
55 ºC
55ºC
51ºC
56ºC
55ºC

Our results for the SNP V89L in SRD5A2 are consistent
with previous metaanalyses that did not find evidence for
a significant main effect of this polymorphism on prostate
carcinogenesis (8,15–17). The V89L site was highly
polymorphic; however, we did not observe any significant
differences in its allele and genotype frequencies between
patients and combined controls, nor between BPH and
population controls or between patients versus BPH or
population controls (Table 3). No association was found
with Gleason score, tumor stage, metastasis, PSA, or age
of diagnosis.
At the SRD5A2 (TA)n repeat site, the (TA)o allele was
the most common in both the cases (84.94%) and the
controls (85.41%), while the (TA)9 allele was less frequent
in the cases (13.6%) and the controls (13.81%) (Table 4).
Statistical analysis did not find any association of (TA)n
polymorphism alleles or genotypes with PC in Bulgarian
patients. Comparisons between PC cases and the 2 groups
of controls separately and between BPH and population
controls were also made, but no statistically significant
differences were observed.
For CYP19A1 (TTTA)n polymorphism, 8 alleles
ranging from 7 to 14 repeats followed a bimodal
distribution, with a peak at 7 repeats and another at 12
repeats (Figure 1). The 7/8 genotype was more frequent
in patients with PC in comparison with one of the most
common genotypes, 7/7; however, this difference did not
reach statistical significance. We were not able to test the
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Table 3. Genotype and allele frequencies of SNP in CYP1B1, CYP19 and SRD5A2 in patients and controls.
Gene/
Polymorphism

CYP1B1,
rs1056836

CYP1B1,
rs1056837

CYP1B1,
rs1800440

CYP1B1,
rs1056827

CYP19, rs700519
(Arg264Cys)

SRD5A2,
rs523349
(Val89Leu)

Genotype/
Allele

Cases

Controls

OR

95%CI

P (two–tailed)

GG

32 (13.4%)

42 (16.73%)

0.77

0.47–1.27

0.32

GC

108 (45.2%)

118 (47.01%)

0.93

0.65–1.32

0.72

CC

99 (41.4%)

91 (36.26%)

1.24

0.86–1.79

0.27

G

172 (36%)

202 (40.24%)

0.83

0.64–1.08

0.19

C

306 (64%)

300 (59.76%)

1.2

0.92–1.55

0.19

CC

99 (41.42%)

86 (34.54%)

1.34

0.93–1.93

0.13

CT

108(45.19%)

121 (48.59%)

0.87

0.61–1.24

0.47

TT

32 (13.39%)

42 (16.87%)

0.76

0.46–1.25

0.31

C

306 (64%)

293 (58.84%)

1.24

0.96–1.61

0.1

T

172 (36%)

205 (41.16%)

0.8

0.62–1.04

0.1

AA

145 (60.67%)

154 (61.85%)

0.95

0.66–1.37

0.85

AG

85 (35.56%)

87 (34.94%)

1.03

0.71–1.49

0.92

GG

9 (3.77%)

8 (3.21%)

1.18

0.45–3.1

0.8

A

375 (78.45%)

395 (79.32%)

0.95

0.7–1.29

0.75

G

103 (21.55%)

103 (20.68%)

1.05

0.77–1.43

0.75

GG

104 (45.41%)

129 (50.19%)

0.83

0.58–1.18

0.32

GT

103 (44.98%)

108 (42.02%)

1.13

0.79–1.62

0.52

TT

22 (9.61%)

20 (7.78%)

1.26

0.67–2.37

0.52

G

311 (67.9%)

366 (71.21%)

0.85

0.65–1.12

0.29

T

147 (32.1%)

148 (28.79%)

1.17

0.89–1.54

0.29

CC

223 (92.53%)

242 (92.72%)

0.97

0.5–1.9

1

CR

18 (7.47%)

18 (6.7%)

1.09

0.55–2.15

0.86

RR

0 (0%)

1 (0.38%)

0

C

464 (96.27%)

502 (96.17%)

1.03

0.54–1.96

1

R

18 (3.73%)

20 (3.83%)

0.97

0.51–1.86

1

VV

17 (6.94%)

24 (16.73%)

0.71

0.37–1.37

0.33

VL

128 (52.24%)

132 (47.01%)

1.01

0.71–1.44

1

LL

100 (40.82%)

98 (36.26%)

1.1

0.77–1.57

0.65

V

162 (33.06%)

180 (35.43%)

0.9

0.69–1.17

0.46

L

328 (66.94%)

328 (64.57%)

1.11

0.86–1.44

0.46

gene dosage effect due to the small number of participants
with the 8/8 genotype in the study. Genotype 8/9 was
more frequent in controls in comparison with patients and
showed a suggestive decrease of PC risk (OR = 0.41, 95%
CI = 0.17–1, P = 0.058, 2-tailed) (Table 5). Genotype 7/12
was more frequent in patients with metastasis (31.43%)
in comparison with controls (17.13%) (OR = 2.22, 95%
CI = 1–4.86, P = 0.062, 2-tailed) (Table 6). Similarly, this
genotype was more frequent in patients with metastasis
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1

(31.43%) in comparison with patients without metastasis
(17.39%) and the result was close to statistical significance
(OR = 2.17, 95% CI = 0.97–4.84, P = 0.064, 2-tailed).
Comparison was made between PC patients with high
(>7) and low (≤7) Gleason scores. The frequency of the
7/12 genotype in patients with less differentiated tumors
(26.09%) was higher in comparison with those with highly
differentiated tumors (12.62%) (OR = 2.44, 95% CI =
1.12–5.39, P = 0.028 2-tailed).
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Table 4. Genotype and allele frequencies of SRD5A2 (TA)n repeat polymorphism in patients and controls.
Patients
(n = 239)

Controls
(n = 258)

OR

P (1-tailed)

P
(2-tailed)

0/0

173 (72.38%)

185 (71.59%)

1.05

0.43

0.84

0/9

53 (22.18%)

67 (26.17%)

0.8

0.19

0.35

9/9

6 (2.51%)

3 (0.78%)

2.19

0.22

0.32

0/8

7 (2.93%)

4 (1.56%)

1.92

0.23

0.37

0

406 (84.94%)

440 (85.41%)

0.99

0.51

1

8

7 (1.46%)

4 (0.78%)

1.9

0.23

0.37

9

65 (13.6%)

72 (13.81%)

0.96

0.44

0.85

Frequency

Genotype/allele

45%
40%
35%
30%
25%
20%
15%
10%
5%
0%

Patients
Controls

7

8

9

10
11
12
Repeat number

13

14

Figure 1. (TTTA)n repeat polymorphism in the CYP19 gene in
patients with PC and controls.

The CYP19 Cys264Arg alteration showed no
association with PC risk or with Gleason score, PSA,
tumor stage, metastasis, or age at diagnosis in Bulgarian
patients. The most plausible explanation for this result is
the low allele frequency of the polymorphic variant and
the small sample size. The observed allele frequency of the
Arg allele was 3.73% among patients and 3.83% among
controls. Homozygous carriers of the polymorphic allele
were not observed among patients and only one was found
among controls.
Among the polymorphic variants in CYP1B1, only
rs1056837 showed any tendency for association with PC.
The frequencies of the C allele and the C/C genotype of the
rs1056837 variant were higher in patients in comparison
with all controls (Table 3), and also between patients and
population controls (OR = 1.46, OR = 1.46, 95% CI = 1.05–
2.04, P = 0.026, 2-tailed for the C allele). The polymorphic
variants in CYP1B1 did not show any correlation with
clinicopathological characteristics.
In Bulgarian patients and controls, a high linkage
disequilibrium was found between the studied
polymorphic variants. The 2-marker haplotype T-T
(rs1056837-rs1056827) was found to be protective. It was
more frequent in controls in comparison with patients (P
= 0.019). The haplotypes A-T-G-T (rs1800440-rs1056837rs1056836-rs1056827; P = 0.062) and T-G-T (rs1056837-

rs1056836-rs1056827; P = 0.043) also showed association
with a decreased risk of PC (Table 7). On the other
hand, none of the haplotype combinations showed any
association with aggressive disease.
The microsatellite (CAG)n in exon 1 of AR with 17
alleles found in patients and controls did not show any
association with PC. The length of the repeats ranged
between 14 and 29–31 with a peak at 21 repeats and
another at 24 repeats (Figure 2). A repeat length of 30
was not observed. There was no significant difference
between the frequencies of the short alleles (14–19 CAG
repeats) among patients and controls. Correlation of the
microsatellite with advanced disease was not observed.
Multigenic analysis was performed but no statistically
significant additive effects or epistatic interactions were
observed. Results from unconditional logistic regression
are shown in Table 8. The polymorphism Cys264Arg was
not included in this analysis due to its very low frequency
in our samples. The polymorphisms rs1056836 and
rs1056837 are in linkage disequilibrium and only one of
them was included in the logistic regression analysis.
4. Discussion
Epidemiologic studies of PC risk factors, including
genetic association studies, are challenging because PC is
a heterogeneous disease (5). Many factors influence the
genetic predisposition for prostate carcinogenesis and
there are differences among populations (18).
In the present study we have explored the association
of polymorphisms in genes implicated in androgen
metabolism including AR, CYP1B1, SRD5A2, and CYP19
with PC. This is the first study in the Bulgarian population
and includes 246 PC patients and controls consisting of
155 BPH patients and 107 unaffected healthy men.
For evaluation of the results 2-tailed P-values were
considered. No correction for multiple testing was
performed, as we consider Bonferroni correction to
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Table 5. Frequencies of the most common genotypes and frequencies of all observed alleles of CYP19 (TTTA)n repeat in patients and
controls.
Genotype/allele

Patients
(n = 242)

Controls
(n = 251)

OR

P
(2-tailed)

7/7

38 (15.70%)

48 (19.12%)

0.79

0.34

7/8

29 (11.98%)

19 (7.57%)

1.66

0.13

7/9

23 (9.50%)

13 (5.18%)

1.92

0.083

7/11

3 (1.24%)

8 (3.19%)

0.38

0.22

7/12

47 (19.42%)

43 (17.13%)

1.16

0.56

7/13

9 (3.72%)

7 (2.79%)

1.35

0.62

8/8

8 (3.31%)

7 (2.79%)

1.19

0.8

8/9

7 (2.89%)

17 (6.77%)

0.41

0.058

8/12

22 (9.09%)

16 (6.37%)

1.47

0.31

8/13

3 (1.24%)

1 (0.4%)

3.14

0.36

8/14

0 (0%)

1 (0.4%)

0

1

9/9

4 (1.65%)

3 (1.19%)

1.39

0.72

9/12

16 (6.61%)

19 (7.57%)

0.86

0.73

9/13

2 (0.83%)

5 (1.99%)

0.41

0.45

12/12

22 (9.09%)

34 (13.54%)

0.64

0.15

7

187 (38.64%)

186 (37.05%)

1.07

0.65

8

78 (16.11%)

68 (13.54%)

1.23

0.28

9

58 (11.98%)

63 (12.55%)

0.95

0.85

10

3 (0.61%)

0 (0%)

Infinity

0.12

11

7 (1.45%)

16 (3.19%)

0.45

0.09

12

133 (27.448%)

152 (30.28%)

0.87

0.36

13

18 (3.71%)

16 (3.19%)

1.17

0.73

14

0 (0%)

1 (0.2%)

0

1

be overly conservative in cases where the tests are not
completely independent.
Unfortunately, we were not able to evaluate the
influence of the studied polymorphisms while taking into
account other factors (diet, smoking, infections, obesity,
diabetes, and others) contributing to PC risk, development,
and aggressiveness. It was not possible to check this in a
stratified group analysis due to lack of sufficient data on
all those confounding factors. This is one of the limitations
of our study and highlights the importance of collecting
prospective clinical and epidemiological data for future
investigations. We are well aware that some of these
environmental factors and comorbid conditions may
interfere with the genetic factors and may even have a
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greater effect on the PC susceptibility and aggressiveness
than the studied polymorphisms alone.
4.1. AR
The growth of the prostate gland depends on circulating
androgens and intracellular steroid signaling pathways.
The effects of androgens are mediated through the
androgen receptor (AR), a nuclear transcription factor
encoded by the AR gene. The common polymorphism,
CAG repeat encoding polyglutamine residues (Q tract), in
exon 1 of this gene has been implicated as a possible risk
factor.
The normal range of CAG repeats is between 8 and 35
and the mean is about 20 repeats. This microsatellite repeat
is associated with differences in AR activity. The shorter
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Table 6. Results from analysis for association of studied polymorphisms with metastasis.
Gene/
polymorphism

Genotype/allele

Cases with
metastasis

Controls

OR

95% CI

P
(2-tailed)

CYP1B1,
rs1056836

GG
GC
CC
G
C

6 (17.65%)
14 (41.18%)
14 (41.18%)
26 (38.24%)
42 (61.76%)

42 (16.73%)
118 (47.01%)
91 (36.26%)
202 (40.24%)
300 (59.76%)

1.07
0.79
1.23
0.92
1.09

(0.42–2.73)
(0.38–1.63)
(0.59–2.55)
(0.54–1.54)
(0.64–1.83)

1
0.58
0.71
0.79
0.79

CYP1B1,
rs1056837

CC
CT
TT
C
T

14 (41.18%)
13 (38.23%)
7 (20.59%)
41 (60.29%)
27 (39.71%)

86 (34.54%)
121 (48.59%)
42 (16.87%)
293 (58.84%)
205 (41.16%)

1.33
0.65
1.28
1.06
0.94

(0.64–2.76)
(0.31–1.36)
(0.52–3.13)
(0.63–1.78)
(0.56–1.58)

0.57
0.28
0.63
0.9
0.9

CYP1B1,
rs1800440

AA
AG
GG
A
G

21 (67.76%)
11 (32.35%)
2 (5.88%)
53 (77.94%)
15 (22.06%)

154 (61.85%)
87 (34.94%)
8 (3.21%)
395 (79.32%)
103 (20.68%)

1
0.89
1.89
0.92
1.09

(0.47–2.1)
(0.41–1.91)
(0.38–9.26)
(0.5–1.7)
(0.59–2)

1
0.85
0.61
0.87
0.87

CYP1B1,
rs105682

GG
GT
TT
G
T

14 (43.75%)
14 (43.75%)
4 (12.5%)
42 (65.62%)
22 (34.38%)

129 (50.19%)
108 (42.02%)
20 (7.78%)
366 (71.21%)
148 (28.79%)

0.77
1.07
1.69
0.77
1.3

(0.37–1.62)
(0.51–2.25)
(0.54–5.31)
(0.45–1.34)
(0.74–2.24)

0.57
1
0.49
0.38
0.38

CC
CR
RR
C
R

33 (94.29%)
2 (5.71%)
0 (0%)
68 (97.14%)
2 (2.86%)

242 (92.72%)
18 (6.7%)
1 (0.38%)
502 (96.17%)
20 (3.83%)

1.3
0.82
0
1.35
0.74

(0.29–5.82)
(0.18–3.69)
–
(0.31–5.92)
(0.17–3.23)

1
1
1
1
1

VV
VL
SRD5A2, rs523349
LL
(Val89Leu)
V
L

2 (5.71%)
19 (54.29%)
14 (40%)
23 (32.86%)
47 (67.14%)

24 (16.73%)
132 (47.01%)
98 (36.26%)
180 (35.43%)
328 (64.57%)

0.58
1.1
1.06
0.89
1.12

(0.13–2.57)
(0.54–2.23)
(0.52–2.18)
(0.52–1.52)
(0.66–1.91)

0.56
0.86
1
0.69
0.69

CYP19, rs700519
(Arg264Cys)

CYP19,
(TTTA)n repeat *

7/7
7/8
7/12
12/12

5 (14.29%)
6 (17.14%)
11 (31.43%)
2 (5.71%)

48 (19.12%)
19 (7.57%)
43 (17.13%)
34 (13.54%)

0.7
2.53
2.22
0.39

(0.26–1.91)
(0.93–6.84)
(1–4.86)
(0.09–1.69)

0.64
0.1
0.062
0.28

SRD5A2,
(TA)n repeat

0/0
0/9
9/9
0/8

27 (77.14%)
7 (20%)
1 (2.86%)
0 (0%)

185 (71.59%)
67 (26.17%)
3 (0.78%)
4 (1.56%)

1.36
0.71
2.5
0

(0.59–3.12)
(0.3–1.71)
(0.25–24.72)

0.55
0.54
0.4

AR,
(CAG)n repeat

Short alleles
Long alleles

4 (11.43%)
31 (88.57%)

25 (16.56%)
126 (83.44%)

0.65
1.54

(0.21–2)
(0.5–4.7)

0.61
0.61

*Results for some genotypes are shown.
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Table 7. Statistical analysis of CYP1B1 polymorphism (1- rs1800440; 2- rs1056837; 3- rs1056836; 4- rs1056827) haplotypes’ associations
with the risk for PC.
Haplotype

Frequency

Case, control ratios

Chi square

P

T

0.011

0.004, 0.017

3.497

0.0615

T

0.011

0.004, 0.017

4.115

0.0425

T

0.014

0.005, 0.022

5.483

0.0192

1

2

3

4

A

T

G

T

G

T

25%
Frequency

20%
15%

Patients
Controls

10%
5%
0%

14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31
Repeat number

Figure 2. CAG repeat polymorphism in AR gene in patients with
PC and controls.

CAG repeat length correlates with higher activity of the AR
and is associated with a risk of developing PC, advanced
cancer, biochemical failure, and associated mortality in
some studies (19). In our cohort of Bulgarian patients and
controls the length of the repeats ranged between 14 and
29 to 31, with a peak at 21 repeats and another at 24 repeats
(Figure 2). Our results for CAG repeat polymorphism in
AR (Tables 6 and 8) are consistent with some recent studies
that did not find any association of this microsatellite with
either PC risk (20,21) or with time to progression, overall
survival, Gleason score, and clinical stage at diagnosis
(22). Conflicting conclusions may be due to differences
in design, small sample size in some studies, differences
in environment, genetic admixture, ascertainment bias
(including diagnosis before or after the age of PSA testing),
and differences in tract length cut off points.
4.2. CYP1B1
As expression of the CYP1B1 gene is elevated in hormonemediated cancers, it has been proposed that it may
affect steroid-related cancer risk. Cytochrome P450 1B1
(CYP1B1) is a member of the CYP1 gene family and is
one of the major enzymes involved in the hydroxylation
of 17β-estradiol (E2) at the C4 position and testosterone
at the C6β and C12α positions (6). No CYP1B1 protein
expression was detected in normal prostate tissue, in
contrast to the overexpression of CYP1B1 protein in
prostate carcinoma. This suggests that CYP1B1 could
biotransform anticancer agents, specifically in target cells,
and play a role in drug resistance. The overexpression
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of CYP1B1 has also been implicated in premalignant
progression but is significantly higher in PC compared
with benign prostate tissue (23).
CYP1B1 is an important enzyme in the activation of
both environmental (polycyclic aromatic hydrocarbons,
heterocyclic and aryl amines, and nitroaromatic
hydrocarbons) and endogenous (estrogen) procarcinogens
to reactive metabolites that cause DNA damage (24). The
importance of CYP1B1 in chemical carcinogens is well
illustrated in animal models, in which metabolites of
CYP1B1 have been shown to induce PC (6).
CYP1B1 is highly polymorphic and its activity and
catalytic specificity are regulated by several functional
nonsynonymous SNPs (3). Many studies have evaluated
the relationship between these SNPs and PC.
Tanaka et al. analyzed the genetic distribution of 6
polymorphisms (both coding and noncoding) in PC
patients and unaffected controls in a Japanese population
(25) and observed that the frequency of polymorphism
in codon 119 (rs1056827) was significantly different
between patients and healthy controls. For the other
polymorphisms in codons 48, 432, and 449, they did
not find any association with PC. The OR of rs1056827
genotype T/T was significantly high compared to wildtype G/G. The genotype T/T variant leading to Ala-to-Ser
substitution at codon 119 of the enzyme displayed the
highest 4-hydroxylation activity among other variants and
was up to 4-fold times higher than the wild type. Products
of this carcinogenic hydroxylation activity have been
shown to cause adenocarcinoma in mice as well as DNA
single-strand breaks, depurination, and mutation (25).
The amino acid Ala119 is located in substrate recognition
site 1 (SRS1) of the enzyme and influences substrate biding
(24,26). In our study we did not find any difference in
genotype or allele frequencies of rs1056827 (Ala119Ser)
among patients and controls as in the study of Chang et
al. (24); however, they observed association with increased
or decreased risk for sporadic prostate cancer of haplotype
combinations in which this polymorphism was included.
Similar to that, certain haplotypes showed association with
prostate cancer in our study.
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Table 8. Results from multivariate unconditional logistic regression for evaluation of the studied polymorphisms and PC risk.
Gene/polymorphism

P

Exp (B) (95% CI)

0.621

0.138

1.861 (0.82–4.22)

TT

0.275

0.414

1.317 (0.680–2.55)

AA

Reference

AG

−0.137

0.581

0.872 (0.54–1.42)

GG

−0.341

0.559

0.711 (0.23–2.23)

GG

Reference

GT

−0.092

0.714

0.912 (0.56–1.49)

TT

−0.373

0.407

0.689 (0.29–1.66)

VV

−0.442

0.256

0.643 (0.30–1.38)

VL

−0.041

0.960

0.960 (0.63–1.46)

LL

Reference

7/8 and 8/8

0.450

0.127

1.568 (0.88–2.8)

7/12

0.406

0.120

1.501 (0.9–2.51)

All other genotypes

Reference

SRD5A2,
(TA)n

Genotypes containing long alleles*

−0.150

0.517

0.861 (0.55–1.35)

All other genotypes

Reference

AR,
(CAG)n

Short alleles**

0.200

0.455

1.222 (0.72–2.1)

Long alleles***

Reference

Constant

−0.362

CYP1B1,
rs1056837

CYP1B1, rs1800440

CYP1B1, rs1056827

SRD5A2, rs523349
(Val89Leu)

CYP19,
(TTTA)n

Genotype

Coefficient B

CC

Reference

CT

0.696

*(TA)8 and (TA)9 are considered for long alleles of the (TA)n SRD5A2 repeat polymorphism.
**Short alleles are 14–19 CAG repeats of the (CAG)n polymorphism in AR.
***Long alleles are 20–31 CAG repeats of the (CAG)n polymorphism in AR.

The frequencies of C allele (64% in patients and 58.84%
in controls) and the C/C genotype (41.42% in patients and
34.54% in controls) of the rs1056837 variant (Asp449Glu)
were higher in patients in comparison with controls (Table
3), but the result did not reach statistical significance. The
CYP1B1 polymorphism rs1056836 alone also has also
shown association with PC analyses (6), but other studies,
including ours, could not confirm this association (25).
CYP1B1*3 (rs1056836) polymorphism is located near the
catalytically important heme-binding domain and leads to
increased expression and catalytic activity of the enzyme
due to change in the tertiary or quaternary structure of the
protein. The CYP1B1*3 polymorphism encodes a protein
that metabolizes estrogen into 4-OHE2 more efficiently,
increasing the intracellular ratio with the minor metabolite
2-OHE2. Thus, castration-resistant PC patients carrying 2

copies of CYP1B*3 had significantly shorter overall-survival
after docetaxel-based therapies (3). Metaanalyses showed
that L432V (rs1056836) had no evidence for association with
PC in the overall population, but after subgroup analysis
by ethnicity, a strong association of this polymorphism
with PC risk in Asians was found (27). In agreement with
these metaanalyses our results demonstrated no statistically
significant association with PC risk in Bulgarian patients
(Table 3), but the result should be confirmed in a larger study.
CYP1B1*4 polymorphisms (rs1800440, N453S) are
not associated with catalytic changes like CYP1B1*3 but
have been associated with decrease in protein expression
due to an increase in the CYP1B1 proteolytic degradation
rate (3). We were not able to find any association of this
polymorphic variant with PC, similar to several other
studies (Table 3) (9).
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Our results were consistent with the previous
observations for association of some haplotype
combinations, including rs1056836, with increased or
decreased risk for sporadic PC. The study of Beuten et al.
showed that a common haplotype C – G – C –C – G – A of
rs2567206, rs2551188, rs2617266, rs10012, rs1056836, and
rs1800440 is inversely associated with PC risk in Hispanic
Caucasians and with aggressive disease status in nonHispanic Caucasian cases. They also found that a second
major haplotype T – A – T – G – C – A was positively
associated with high-grade disease in non-Hispanic
Caucasians (6). Association of T-C/T-C diplotypes of
rs1056827 and rs1056836 with aggressiveness has been
found by Cicek et al. (26).
In the present study we did not observe an association
between the haplotype combinations of studied
polymorphic variants and disease aggressiveness, but we
found statistically significant association of the haplotype
T – G – T (rs1056837-rs1056836-rs1056827) (P = 0.043)
and T – T (rs1056837-rs1056827) (P = 0.019) with
decreased PC risk in Bulgarian patients (Table 7).
4.3. CYP19
This cytochrome P450 enzyme is present in the gonads and
in the extragonadal tissue, including the fibromuscular
stroma of prostate and adipose tissue (28,29). CYP19
encodes the enzyme aromatase that catalyzes the
irreversible conversion of androstenedione to estrone
and of testosterone to estradiol (13,30). These reactions
are the last steps of estrogen biosynthesis (5). Lack of
normal function could affect testosterone concentrations,
in turn influencing the risk of PC (9). Aromatase mRNA
and protein have both been detected in BPH and PC
tissue (29). In light of these data, normal and benign
prostates clearly have the capacity to locally metabolize
androgens to estrogens via aromatase. The hormone
balance and the ratio of androgens to estrogens play a
pivotal role in prostate disease, particularly during later
life (1). Significantly, the intraprostatic hormone levels
do not always mirror systemic levels and, ultimately, the
local hormone levels are those that are important for
the maintenance of the prostatic health, as well as the
development and progression of prostate disease (1,10).
Aromatase is expressed locally within the prostate and
is aberrantly expressed in PC. Specifically, the induction
of expression and altered promoter utilization with
malignancy imply a shift in the local hormone balance and
T:E (androgen:estrogen) ratio (1). Moreover, circulating
estrogens can compete with androgens for binding to sex
hormone-binding globulin, and it is generally assumed that
sex hormone-binding globulin synthesis is regulated by
and is a reflection of androgen/estrogen balance (14). This
balance is critical for prostate health, and, consequently,
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any alteration in aromatase expression has the potential to
shift this balance and exert profound effects via ERα, ERβ,
and/or nonreceptor mediated effects (1). Therefore, it has
been suggested that genetic variations in the aromatase
gene CYP19 alter an individual’s risk of PC.
Several studies have investigated the role of different
CYP19 polymorphisms in PC. The most extensively
studied polymorphisms are rs700519 (Arg264Cys, 27142C
> T) in exon 7 and tetranucleotide repeat (TTTA)n in
intron 4 with 7 alleles ranging in length from 7 to 13. The
(TTTA)n repeat polymorphism is not close to any intronic
splice sites, and therefore it is unlikely that it directly
affects aromatase activity (10). It has been reported that
the long allele of this repeat polymorphism is associated
with early-onset PC (13) in one study, with PC risk in
familial cases in another (31), and with poor survival in
PC patients with bone metastasis at diagnosis in a third
(32). In concordance, in our study we found that the long
allele in genotype 7/12 increases the risk for development
of metastasis (Table 6), but it was not possible to test allele
dosage effect due to the rare 12/12 genotype and the small
number of patients with metastasis.
Tang et al. found that the 8-repeat allele is more
common in cases than in controls and the 7/8 genotype
is significantly associated with an increased risk of PC,
regardless of Gleason score, similar to our results. They also
observed differences in serum estrone levels depending on
individuals’ genotypes. The 8/8 genotype had the highest
levels of serum estradiol and estrone and the lowest level
of serum testosterone (10). In our study there was no way
to test the gene-dosage effect due to the low numbers of
participants with the 8/8 genotype (Table 5).
There were studies that could not confirm the
association of (TTTA)n polymorphism with PC (33).
Furthermore, no association between pathological grade
or stage, patient’s age at onset, or preoperative PSA and
repeat polymorphism was found by Cunningham et al.
(34) and Latil et al. (31).
Cussenot et al. found an additive effect when they
combined 2 risk alleles, rs1056836 in CYP1B1 and the long
allele of (TTTA)n in CYP19 (13), -but in our study we did
not observe such a cumulative effect.
The polymorphism Arg264Cys is located in exon 7, and
the C-to-T substitution in nucleotide 826 leads to an Arg to
Cys change at codon 264 (12). It shows a tendency toward
increased risk, especially with high-grade carcinoma (14).
Modugno et al. evaluated the effect of the AR CAG repeat
length and the aromatase genotype of rs700519. They
found that short AR and C/T genotypes of aromatase have
a 3-fold increase in risk for PC in a Japanese population
(14). Using a “super control” group composed of male
Sicilian centenarians, Balistreri et al. observed a significant
difference in genotype distribution of Arg264Cys between
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PC patients and controls (12). However, other large studies
have failed to confirm the association of rs700519 with PC
in different populations (18).
Travis et al. made a comprehensive study of the genetic
variation at CYP19 locus in relation to PC risk and to
circulating steroid hormone concentrations in men from
the Breast and Prostate Cancer Cohort Consortium.
They analyzed 21 SNPs, including rs700519. Their results
suggested that, although germline variations in CYP19A1
characterized by the haplotype-tagging SNPs produce
measurable differences in sex hormone concentrations
in men, they do not substantially influence the risk of
PC (28). In our study, rs700519 also did not show any
association with PC (Table 3).
4.4. SRD5A2
Steroid 5-α-reductase type 2 (SRD5A2) is a critical enzyme
in androgen metabolism (8,15). The SRD5A2 gene encodes
a membrane-bound enzyme, SRD5A2, which catalyzes the
irreversible conversion of testosterone into a more potent
androgen, dihydrotestosterone (DHT) (8). DHT binds to
AR, and the DHT-AR complex stimulates the transcription
of several genes with androgen responsive elements (5).
The AR is normally associated with heat shock proteins in
an inactive state. Androgen binding induces dissociation
from heat shock proteins, hyperphosphorylation,
conformational changes, and dimerization of the receptor.
The binding affinity of DHT to the prostatic AR is 5 times
higher than that of testosterone (29).
In humans, two 5α-reductase isoenzymes have been
identified. The type 2 enzyme (encoded by the SRD5A2
gene) is localized primarily in androgen target tissue,
including genital skin and the prostate gland. Type 2
enzyme is involved in prostate development and growth.
DHT is mainly responsible for prostate growth,
and it has been demonstrated that tissue DHT level is a
useful marker in predicting the clinical response of PC
to antiandrogen therapy. The levels of DHT and resulting
androgen action vary among different individuals
depending on the activity of 5α-reductase (5).
It has been shown that young Japanese men have lower
5α-reductase activity than young Caucasian-American
and African-American men. DHT to testosterone ratio
was highest in African-Americans, intermediate in
Caucasian-American, and lowest in Asian-Americans,
corresponding to the respective risk of developing PC in
these groups (15).
Certain SRD5A2 polymorphisms may encode
5α-reductase enzyme variants with different activities,
probably due to altered mRNA stability (29). A number
of mutations/polymorphisms have been identified in the
SRD5A2 gene; however, A49T, V89L, and (TA)n repeat
polymorphisms are the most frequent. No clear consensus
has been reached on the association between them and PC
risk (15).

Markidakis et al. reported for the first time the missense
substitution in the SRD5A2 gene, which replaces valine at
codon 89 with leucine. The V89L substitution results in
an almost 30% reduction of reductase activity both in
vitro and in vivo (35). It has been reported that the leucine
allele reduces almost 30% of androstanediol glucuronide,
a serum marker of 5α-reductase activity, among Asian
men. Among Caucasian men, a 10% insignificantly lower
androstanediol glucuronide level has been observed in
individuals with the L/L genotype (12).
This polymorphism has different distributions
in various ethnic groups and populations. It has low
frequency in the African-American population and it is
most common in Chinese and Japanese populations, who
have the lowest risk for PC among the different racial
groups (8).
Several studies supported the association of V89L and
PC risk. In support of the finding that the distribution of
V89L genotypes parallels the patterns of PC incidence in
high- and low-risk populations, some authors have found
that the Val allele increases the risk for PC in different
populations (36). Conversely, other authors claimed that
the Leu allele is responsible for increased PC risk (37).
Despite the studies that find a correlation of V89L with
PC, the metaanalysis of Li et al. (8), including 24 casecontrol studies, and of Li et al. (15), including 31 studies,
found that PC was not associated with this variant. The
last metaanalysis including all 45 eligible studies of PC
since January 1995 and combining a total of 15,562 cases
and 15,385 controls also reported a lack of significant
associations between V89L polymorphism and PC
under all genetic models (38). Thus, our results for V89L
polymorphism support the findings from the metaanalyses
(Tables 3 and 8).
Another polymorphism in SRD5A2 that has been
extensively studied is the (TA)n dinucleotide repeat
(rs10529926) on the 3’ UTR region. Originally, 3 alleles
were identified: (TA)0, (TA)9, and (TA)18. The most
common allele, accounting for 96% of the chromosomes,
was (TA)0. The observation that the rare (TA)18 allele was
limited to African-Americans, who have a higher rate of
PC than Asian-American or Caucasian men, suggested
that a longer allele might be associated with increased
enzyme activity (39). The repeat was thought to cause
instability of mRNA transcripts with UA-rich 3’ UTRs
but no association of the (TA)n variation with serum
3α-androstanediol glucuronide level was observed (5).
Longer alleles were associated with a modest, insignificant
decrease in PC risk, although some studies have failed
to confirm this association. No association with PC was
found for this polymorphism in a British population, in
Caucasians and Asians, and only a modest association was
found in a South Indian population (15). Our results show
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that (TA)n repeat polymorphism is not associated with
PC risk in a Bulgarian population (Tables 4 and 8), but a
larger sample size needs be studied in order to confirm this
conclusion (Table 4).
The metaanalysis of Li et al., including 31 association
studies, concluded that there was a significant association
between PC and the (TA)n polymorphism, with a long TA
repeat decreasing the PC risk as compared with a short TA
repeat (15).
Consequently, the biochemical effects of SRD5A2
polymorphisms on enzymatic activities or androgen levels
remain controversial, but, on the other hand, androgen
deprivation therapy reduces the risk of PC recurrence and
death, and chemoprevention with finasteride reduces PC
incidence by approximately 25% (8). Another metaanalysis
showed that (TA)n repeat polymorphism and A49T have
some effect on PC risk but the probably additive effects of
different loci have to be considered to evaluate the risk. In
our study we did not observe any additive effects between
the studied polymorphisms, probably due to small sample
size.
Briefly, we have evaluated the role of polymorphisms
in the androgen metabolism genes AR, CYP1B1, CYP19,
and SRD5A2 for PC development in Bulgarian patients.
The allele and genotype frequencies of most of the
studied variants did not significantly differ between
cases and controls. An increased frequency in PC cases
in comparison with controls was observed for the C/C
genotype and C allele of rs1056837 in CYP1B1, and
genotype 7/8 of the (TTTA)n repeat polymorphism in
CYP19A1. Some tendency for association with decreased
PC risk and the risk for developing metastasis was shown
for the 8/9 genotype and the 7/12 genotype of the same
polymorphism, respectively.

For the polymorphisms in CYP1B1 we performed a
haplotype analysis in order to check their cumulative effects.
The CYP1B haplotypes T – T (rs1056837-rs1056827; P =
0.019) and T – G – T (rs1056837-rs1056836-rs1056827; P
= 0.0425) showed statistically significant association with
PC risk reduction.
In conclusion, the polymorphisms in the CYP1B1 gene
are probably associated with PC risk in Bulgarian patients
since we obtained statistically significant results for some
haplotype combinations. Some genotypes of the (TTTA)n
repeat polymorphism in CYP19 also showed association
with PC susceptibility or aggressiveness.
Our results suggested that the polymorphisms V89L
and (TA)n repeat in SRD5A2, as well as the CAG repeat
in AR and the Arg264Cys variant in CYP19A1, most likely
were not associated with PC in this Bulgarian population.
The polymorphic variant Arg264Cys in CYP19 was too
rare to make meaningful conclusions for its impact on PC
risk.
Even though the present data are consistent with some
previous results from other populations and metaanalyses,
further studies with larger sample sizes are needed to
elucidate the contribution of the androgen metabolismrelated polymorphisms to the risk of PC in Bulgarian men.
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